AZN - Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
2024-06-20 12:45:04 ET
Summary
- Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval.
- Potential competition from Sanofi / Regeneron's Dupixent poses a threat, but Verona may have a head start in the market thanks to a delay in the PDUFA for Dupixent.
- Verona's market cap undervalues its potential success, with potential for significant growth and M&A interest.
- Incumbents in the COPD space include GSK's advair and AstraZeneca's symbicort - this makes the commercial launch of ensifentrine potentially tricky.
- Nevertheless, the strong safety and efficacy profile and its differentiated MoA mark it out as a potential "blockbuster" drug, which makes a relatively persuasive bull case for Verona stock.
Investment Overview - Approval Catalyst One Week Away In Large, Underserved COPD Market
London, United Kingdom-based Verona Pharma plc ( VRNA ) has a Prescription Drug User Fee Act ("PDUFA") date upcoming for its lead and only drug candidate, ensifentrine, on June 26th - in less than a week - in the indication of Chronic Obstructive Pulmonary Disease ("COPD")....
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst